Corporate Information – Page 6

iZafe Group signs agreement with new partner in the United Kingdom worth at least SEK 18.7 million.

iZafe Group AB ("iZafe Group") hereby announces that the company has signed an exclusive collaboration agreement with Targeted Outcomes for the rights to sell and market the pharmaceutical robot Dosell in the United Kingdom for a period of 5 years. Targeted Outcomes' minimum commitment over a five-year period amounts to SEK 18.7 million, after which a recurring license revenue of at least SEK 7.9 million annually will be generated.

Targeted Outcomes' annual minimum commitment for the purchase of Dosell increases annually during the agreed 5-year period. The minimum agreed sales volume amounts to a total of 1,810 Dosell units.

"We are pleased that more players want to take part in our products outside of Sweden. The United Kingdom is a very interesting market with great potential, expected to show increased demand for digital aids for safer medication at home. We have long been searching for the right partner to enter the UK market. The choice to collaborate with Targeted Outcomes is due, among other things, to their solid experience in medical technology and their broad industry contacts," says Anders Segerström, CEO of iZafe Group.

Targeted Outcomes is a medication management company that helps patients and prescribers better adhere to medication regimens and thus improve patients' health. The company was founded by Andrew Burr, an independent prescriber and clinical pharmacist with experience in implementing medication management programs in both private and public health sectors, and Andy Beesley, with experience in helping pharmacies distribute automated solutions to improve medication adherence.

"The agreement with Dosell supports a range of initiatives that will begin in 2023 to test the service in home care, nursing homes, and virtual care wards. The most expensive medication for the NHS is the one the patient is prescribed but does not take. If we succeed in improving medication adherence, we will directly improve the outcomes patients experience. Dosell has enormous potential to achieve this and improve pharmacists' contribution to patient care overall," says Andrew Burr.

"Our agreement with Dosell enables Targeted Outcomes to deliver a truly innovative and cost-effective solution. Through collaborations, we aim to prove that a holistic approach to medication management by bringing together pharmacies, care agencies, and service users will deliver benefits for all parties," says Andy Beesley.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

iZafe Group signs agreement with new partner in the United Kingdom worth at least SEK 18.7 million.

AAA IMG 0022

iZafe Group announces exclusive agreement to sell 1,000 Dosell annually

iZafe Group AB ("iZafe Group") announce that it has signed an exclusive partnership agreement with IVE Ventures (“IVE”) for the right to exclusively sell and market the Dosell medication robot in the Netherlands. IVE has committed to purchasing a minimum of 1,000 Dosell units annually for a three-year period in order to maintain exclusivity. The total value of hardware purchases and licensing revenue amounts to approximately SEK 16 million for the first three years, with an annual recurring licensing revenue of at least SEK 6 million thereafter.

IVE has placed an initial order for 1,000 Dosell units and has a minimum commitment of 1,000 Dosell units per year to maintain exclusivity for the Netherlands.

IVE has been offering a range of connected health services since 2014. In recent years, IVE has expanded its portfolio to include products from Teltonika, Vayyar, Vivago, Eview, and Withings. IVE has chosen to include Dosell in its portfolio in order to expand its range with a groundbreaking digital medication robot. By distributing Dosell, IVE can better support its existing care and alarm center customers in the Netherlands with a reliable and proven safe medication solution. IVE aims to commercially launch Dosell in the Dutch market in the second quarter of 2023.

“This agreement is another great step forward for IVE. We have been assessing the market of providing safe and reliable medication dispensing for the past 24 months. When meeting Dosell, we quickly realized that they share the same vision to provide reliable connected health solutions. The short integration time for market introduction, that lasted only 8 weeks, solidifies our believe that our shared DNA will allow us to act and react agile on the challenges which the Healthcare industry faces today. Dosell covering a key part of our connected health portfolio, allowing us to fulfil our mission: keeping our loved ones independent and safe in the easiest, surest and most economical way.” Says Martijn Van Bree, Managing Director of IVE Ventures.

"Since we launched a consumer version of our medication robot Dosell, we have received great demand internationally. I am very pleased that we are reaching this important milestone. Breaking into the Dutch market, which is the market that has come the furthest in packaging medicine in sachets, is significant. That IVE also chooses to invest heavily in our medication robot Dosell after reviewing all competitors in the market is also a testament to the strength of Dosell's potential for international success," says Anders Segerström, CEO of iZafe Group.

About IVE Ventures

IVE Ventures was founded in 2014 to invest into, distribute and operate a range of connected services within the Smart Mobility and Connected Health sector. Within the group, IVE’s subsidiaries include a service provider for connected health services (ICE Alarm the Netherlands), a 24/7 multilingual Medical Service Center (ICE Alarm España) and a provider of smart mobility solutions for insurance companies (ICE Protect the Netherlands). Operating out of offices in both the Netherlands and Spain, IVE is trusted by several major insurance and security companies who rely on IVE to provide mission-critical solutions to its clients.

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

In November 2022 iZafe Group AB ("iZafe" or the "Company") acquired Pilloxa AB and, in connection with the acquisition, carried out a directed issue of units consisting of shares of series B and warrants of series TO13B. To compensate existing shareholders for the dilution from the directed issue of units, and with the purpose of capitalizing iZafe in a favorable way, the Company issued warrants of series TO13B free of charge to all shareholders. A total of 118,556,833 warrants of series TO13B were issued. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price has been set to SEK 0.20 per share of series B. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023.

Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO13B shall correspond to 70 percent of the
volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the measurement period from and including February 9, 2023, up to and including February 22, 2023. However, not lower than the quota value for the Company's share, corresponding to SEK 0.20, and not higher than SEK 0.30 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.21. Thus, the subscription price is determined to SEK 0.20. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023. Complete terms and conditions for the warrants of series TO13B are available on the Company's website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

About Us

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

iZafe has been granted a new patent for safer medication handling at home

iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for medication delivery arranged to adjust a pre-defined and pre-packaged medication dose based on a patient-specific parameter," applies to the company's technology for medical and digital security solutions to create safer medication management in the home.

"This patent gives us additional protection in Sweden for medication handling at home. After the acquisition of Pilloxa, we are able to offer solutions for safe medication for the entire patient journey, which in practice means the following steps:
• Pill jars or other loose medicine in syringes, tablets or liquid form. Where, with the help of our app, we remind, show statistics and can send alarms.
• Sorting in "dosett" where we offer a smart connected version that, with the help of our app, helps with sorting, reminders, alarms and statistics.
• Medication in sachets where, with the help of Dosell, we automate the entire process in the medication.
With this patent, we can also create a unique solution for safer medication handling in the home and addressing a significent and increasing demand" says Anders Segerström, CEO of iZafe Group.

About Us

iZafe has been granted a new patent for safer medication handling at home

The medication robot Dosell is being implemented in two new municipalities

iZafe Group (publ.) hereby announces that the partner Careium Sweden AB is now starting the implementation of Dosell in two more municipalities in Sweden.

The municipalities, which together have approximately 13,500 residents aged 65 and over, initially start with 10 Dosells and then gradually increase the number.

Lack of adherence to medication is a major societal problem, which requires large resources to deal with. Dosell solves medication management in an efficient way and thus frees up the staff's time for care.

"We look forward to continuing the implementation of Dosell in more municipalities in the future and thereby working for greater independence for care recipients," says Martin Puumalainen Director Nordics and International for Careium AB

About Careium
Careium is one of the leading players in welfare technology in Europe and around 400,000 people use their services. The vast majority of these are connected to one of the company's four alarm centers in Sweden, Norway and Great Britain. The alarm centers receive more than 25,000 alarms a day. Read more at careium.com

About Us

The medication robot Dosell is being implemented in two new municipalities

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

As announced by press release on November 28, 2022, the Board of Directors of iZafe Group AB (publ) ("iZafe" or the "Company") has decided to distribute warrants free of charge to shareholders in the Company. The record date for allotment of warrants of series TO13B has been set to December 23, 2022. The exercise period to subscribe for new shares with the support of warrants of series TO13B will be from and including February 23, 2023, to and including March 8, 2023. The first day of trading in the warrants of series TO13B on Nasdaq First North Growth Market will be on December 28, 2022.

As announced by press release on November 28, 2022, iZafe has completed a directed issue of shares and warrants of series TO13B (the “Directed Issue”). In order to give existing shareholders in the Company the opportunity to compensate for the dilution the Directed Issue entails, the Board of Directors of iZafe has also decided to issue warrants of series TO13B (same series as in the Directed Issue) to the Company, which then are allotted free of charge to the shareholders in the Company.

The record date to receive warrants of series TO13B has been set to December 23, 2022. Therefore, the last day of trading in the Company’s share including the right to receive warrants is December 21, 2022, and the first day of trading in the Company’s share excluding the right to receive warrants is December 22, 2022.

The Company’s existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date.

Terms and information regarding warrants of series TO13B

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023, to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent of the numbers of shares and approximately 42.69 percent of the votes.

Advisors
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the warrants of series TO13B.

About Us

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe Group AB (publ) hereby announces that the company has entered into an agreement with Mangold regarding the service as Certified Adviser.

Mangold will take over as Certified Adviser (CA) on 1 April 2023. Until then, FNCA will continue to act as Certified Adviser for the company.

About Us

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with ApoEx AB, which is a supplier of pharmacy services, systems and dosage bags to privately and publicly run healthcare providers.

“iZafe and the medicine robot Dosell are the only products on the market that can handle the dose bags that we deliver to our customers in outpatient and inpatient care. We are happy to develop the collaboration with iZafe, which is completely in line with our business concept of offering technical solutions to customers in public and private healthcare”, says John Patrick Berlips, licensed physician and founder of ApoEx.

ApoEx supplies dose bags to 3,500 patients and hospitals in several of the country's regions. In Stockholm, the company produces the sachets that, among others, Aleris uses in its healthcare deliveries.

“ApoEx offers smart comprehensive solutions of goods and services for both private and public healthcare and is therefore the right partner for us. As iZafe is currently in an expansive phase, our strategic partnerships are absolutely crucial for us. With these collaborations, we can more effectively develop successful solutions together”, says Anders Segerström, CEO of iZafe.

About ApoEx
ApoEx was founded in 2010 with the aim of simplifying and improving care. We have developed most solutions in close dialogue with our customers and the business is characterized by customer-driven innovation and the attitude that nothing is impossible. Over the years, thousands of healthcare companies in the private and public sector have chosen ApoEx as their strategic partner for the supply of medicines and consumables.

About Us

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with Medcam AB, which sells medical technology products to healthcare in the Nordics and Europe. In the first place, the focus will be on the Dutch market, but the company has the potential for several countries in the near term.

"We have a high demand for products that enable a more digital healthcare where medication and compliance are an important factor. The pharmaceutical robot Dosell is a perfect complement to this, ensuring compliance in a safe way, while being integrated to enable more proactive and digital care.
The Dutch market has very great potential and we are starting this collaboration, as the demand from our customers is high for pharmaceutical robots", says Robert Camara, CEO of Medcam.

"The Dutch market has long been a goal for us to enter, as it is the country that has come the furthest in Europe regarding medication in sachets. We are now ready to start more collaborations that enable us to expand to several markets and look forward to starting work with Medcam and their customers", says Anders Segerström, CEO of iZafe Group.

About Medcam
MedCam AB markets and sells medical technology products and focuses on high quality products from stable suppliers. The company's business concept is to supply the Nordic and European market with high-quality products at good prices with high service.
The company's suppliers are located all over the world, i.a. USA, France, Germany and China. Medcam constantly strives to be able to satisfy customers' needs and demand and continuously searches the market, in order to be able to offer better and innovative products now and for the future.
For more information, read more at www.medcam.se

About Us

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

iZafe Group AB (publ.) (”iZafe” or the ”Company”) today announces the outcome of the exercise of warrants of series TO10B, which were issued during the fourth quarter of 2021. In total, 12,072,688 warrants of series TO10B were exercised, corresponding to approximately 34.1 percent of the total number of outstanding warrants of series TO10B, for subscription of 12,072,688 B-shares at a subscription price of SEK 0.26 per B-share. iZafe will receive approximately SEK 3.14 million before issuing costs through the exercise of the warrants of series TO10B.

Background
The subscription period for exercise of the warrants of series TO10B took place from September 27, 2022, up to and including October 11, 2022. The subscription price per B-share for exercising the warrants of series TO10B was set to SEK 0.26.

In total, 12,072,688 warrants of series TO10B were exercised for subscription of 12,072,688 B-shares, meaning that approximately 34.1 percent of all outstanding warrants of series TO10B were exercised for subscription of B-shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to B-shares within approximately three (3) weeks.

Number of shares, share capital and dilution
Through the exercise of the warrants of series TO10B, the number of shares in iZafe increases by 12,072,688 B-shares, from 70,874,308 shares (consisting of 600,000 A-shares och 70,274,308
B-shares) to a total of 82,946,996 shares. The share capital will increase by SEK 2,414,537.60 from SEK 14,174,861.60 to SEK 16,589,399.20.

For existing shareholders who did not exercise any warrants of series TO10B, the dilution amounts to approximately 14.6 percent of the number of shares and approximately 13.7 percent of the number of votes in the Company.

About Us

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million